All In Biotech

Drug Trial Radar · NCT01924793

An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection

Last checked: Nov 19, 2026Latest source record: Jul 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Aug 2013

Primary completion

May 2017

Study completion May 2017

Sponsor

Lead sponsor
Ansun Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Aug 19, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection. All subjects will have additional PK and Immunogenicity blood samples collected.

Conditions

  • Parainfluenza

Interventions

  • DAS181-F02 Dry Powder in BulkDrug

    Administered via DPI

  • DAS181-F02 Nebulized Formulation Inhaled DoseDrug

    Administered via Nebulizer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative incidence and severity of AEs, SAEs, and lab abnormalities as a measure of safety and tolerability.Time frame: 2 years

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Children's Hospital of Orange County

    Orange, California

  • Stanford University Medical Center

    Palo Alto, California

  • University of Chicago

    Chicago, Illinois

  • Indiana Blood and Marrow Transplantation

    Indianapolis, Indiana

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • John Hopkins University School of Medicine

    Baltimore, Maryland

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • University of Minnesota, School of Medicine

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Weill Cornell Medical College/New York Presbyterian Hospital

    New York, New York

  • Weill Cornell Medical College-Peds

    New York, New York

  • Duke University

    Durham, North Carolina

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • University of Oklahoma

    Oklahoma City, Oklahoma

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

  • Fred Hutchinson Cencer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.